Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 2/20 | 0.54 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.51 |
| ▸ | PRNP | P04156 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30507087 | 1.00 | CXCR1 (0.54) | CXCR1CXCR2HPGDKMT2APOLB | |
| SCHEMBL12045690 | 0.81 | CXCR1 (0.54) | CXCR1CXCR2HPGDPOLBRXFP1 | |
| SCHEMBL342319 | 0.80 | ALDH1A1 (0.49) | CXCR2HPGDKMT2APOLBRXFP1 | |
| SCHEMBL28488328 | 0.76 | KDM4E (0.47) | KMT2APOLBALDH1A1MEN1TDP1 | |
| SCHEMBL15549840 | 0.75 | HSD17B10 (0.57) | HPGDKMT2APOLBRXFP1PRNP | |
| SCHEMBL3759901 | 0.74 | LMNA (0.72) | HPGDKMT2APOLBRXFP1ALDH1A1 | |
| SCHEMBL30825924 | 0.73 | CXCR1 (0.46) | CXCR1CXCR2HPGDKMT2APOLB | |
| SCHEMBL27261477 | 0.73 | CXCR1 (0.46) | CXCR1CXCR2HPGDKMT2APOLB | |
| SCHEMBL25934647 | 0.73 | ALDH1A1 (0.40) | CXCR2HPGDKMT2APOLBALDH1A1 | |
| SCHEMBL19385660 | 0.73 | CYP11B1 (0.49) | TDP1MAPTMAPK1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| EP-4465982-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| US-11976067-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20160256447-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES INC (US) | 2016-09-08 | — | — | US | disclosed |
| US-9181219-B2 | Compounds of modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140011840-A1 | Compounds of Modulating TRPV3 Function | HYDRA BIOSCIENCES, INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-8389546-B2 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120015979-A1 | Compounds for Modulating TRPV3 Function | Hydra Biosciences, Inc, (US) | 2012-01-19 | — | — | US | disclosed |
| US-7998980-B2 | Transient Receptor Potential channel modulators; N-(2-pyridinyloxy- or 2-pyridinylthio-alkanoyl)quinolines; acute or chronic pain, sensitivity, burns, diabetic neuropathy, psoriasis, eczema, dermatitis, post-herpetic neuralgia, migraine, incontinence, fever, hot flashes, osteoarthritis; depilatories | HYDRA BIOSCIENCES, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20080146611-A1 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES INC. (US) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160256447-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | TRPV3, TRPV1, TRPV4 | CXCR1 3006/4885CXCR2 981/4885HPGD 797/4885 |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | CXCR1 1785/4885CXCR2 1225/4885HPGD 3815/4885 |
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | CXCR1 1911/4885CXCR2 1231/4885HPGD 3855/4885 |
| US-20120015979-A1 | Compounds for Modulating TRPV3 Function | TRPV3, TRPV1, TRPV4 | CXCR1 3006/4885CXCR2 981/4885HPGD 797/4885 |
| US-20140011840-A1 | Compounds of Modulating TRPV3 Function | TRPV3, TRPV1, TRPV4 | CXCR1 2970/4885CXCR2 953/4885HPGD 798/4885 |
| US-20080146611-A1 | Compounds for modulating TRPV3 function | TRPV3, TRPV1, TRPV4 | CXCR1 3006/4885CXCR2 981/4885HPGD 797/4885 |
| US-11976067-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, LDLR | CXCR1 1785/4885CXCR2 1225/4885HPGD 3815/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | CXCR1 1911/4885CXCR2 1231/4885HPGD 3855/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | CXCR1 1911/4885CXCR2 1231/4885HPGD 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.